BALA CYNWYD, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Qualtrics (Nasdaq - XM)

Under the terms of the deal, Qualtrics will be acquired by Silver Lake. Silver Lake will pay $18.15 in cash for each share of Qualtrics common stock in a deal valued at approximately $12.5 billion. The investigation concerns whether the Qualtrics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Silver Lake is paying too little for the Company. For example, the deal consideration is below the 52-week high of $30.95 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/qualtrics-nasdaq-xm/.

Seagen Inc. (Nasdaq - SGEN)

Under the terms of the agreement, Seagen will be acquired by Pfizer Inc. (NYSE - PFE). Pfizer will pay $229.00 in cash for each share of Seagen common stock in a deal with an enterprise value of approximately $43 billion. The investigation concerns whether the Seagen Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Pfizer is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/seagen-inc-nasdaq-sgen/.

Provention Bio Inc. (Nasdaq - PRVB)

Under the terms of the agreement, Provention will be acquired by Sanofi (Nasdaq - SNY). Sanofi will pay $25.00 in cash for each share of Provention common stock in a deal valued at approximately $2.9 billion. The investigation concerns whether the Provention Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Sanofi is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/provention-bio-inc-nasdaq-prvb/.

Kimball International, Inc. (Nasdaq – KBAL)

Under the terms of the Merger Agreement, Kimball will be acquired by HNI Corporation (NYSE - HNI). Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own. As a result of the transaction, Kimball shareholders will own approximately 10% of the combined company. The investigation concerns whether the Kimball Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Kimball shareholders in the combined company and whether HNI is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/kimball-international-inc-nasdaq-kbal/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.